Ignite Creation Date:
2024-05-06 @ 1:48 PM
Last Modification Date:
2024-10-26 @ 1:20 PM
Study NCT ID:
NCT04137900
Status:
RECRUITING
Last Update Posted:
2024-02-05
First Post:
2019-10-21
Brief Title:
Safety Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator BTLA as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Sponsor:
Organization:
TopAlliance Biosciences
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
499
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: